Blockbuster Dreams
New understanding of the biology behind a successful cancer therapy may lead to a drug that can treat an array of solid tumors
By Gary Stix
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
From the time it was approved in 1998, Genentech's Herceptin--a drug in the vanguard of the first generation of so-called targeted therapeutics--has achieved an impressive track record for a subset of breast cancer patients. Some patients who take it live longer and the size of their tumors is kept under better control than if they had received standard chemotherapy alone.
To develop Herceptin, researchers at Genentech drew on investigations into the molecular workings of a cancer cell. Some breast cancer cells stud their exterior with a surfeit of receptors that join in pairs to trigger a cascade of signals that cause the cells to replicate uncontrollably, develop resistance to chemotherapy and encourage the growth of blood vessels that promote the spread of tumor cells.
Subscribe to Support Independent Journalism
Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.
When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.
Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber
